Adrizzone 2006 |
Trial does not have a placebo, SASP or other formulation of 5‐ASA comparison group. Trial compares 5‐ASA versus azathioprine |
Ahluwalia 1992 |
Dose‐ranging study. The study does not provide details on pre‐specified outcomes |
Gross 2011 |
Trial does not have a placebo, SASP or other formulation of 5‐ASA comparison group. Trial compared once daily dosing of mesalazine (Salofalk) with once daily budesonide |
Irvine 2008 |
Pooled quality of life data from two RCTs (ASCEND I and ASCEND II) |
Kamm 2009 |
Not a RCT ‐ open‐label extension study |
Mahmood 2005 |
Oral 5‐ASA combined with trefoil factor 3 enema versus oral 5‐ASA combined with placebo enema |
Paoluzi 2002 |
Trial looks at 4 weeks of combined oral and topical 5‐ASA (mesalazine) versus 8 weeks of combined oral and topical 5‐ASA (mesalazine) |
Pruitt 1991 |
Single‐centre report abstracted from a larger multicenter trial (Sninsky 1991) |
Safdi 1997 |
Trial compared oral mesalamine (Asacol) to mesalamine enema (Rowasa) to combination of oral mesalamine and enema |
Vecchi 2001 |
Trial compared oral 5‐ASA (Salofalk) + placebo enema to oral 5‐ASA + 5‐ASA enema (Salofalk) |
Vernia 2000 |
Trial compared oral mesalazine to combination of oral mesalazine + oral sodium butyrate |